Results 181 to 190 of about 3,251,164 (295)
Molecular Oncology, EarlyView.TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach +8 more
wiley +1 more source
New Horizons in Therapeutic Nerve Block in the Treatment of Vascular and Renal Emergencies [PDF]
, 1948 Robert A. Hingson +4 more
openalex +1 more source
Molecular Oncology, EarlyView.Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner +6 more
wiley +1 more source
Molecular Oncology, EarlyView.A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul +11 more
wiley +1 more source
Molecular Oncology, EarlyView.Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva +5 more
wiley +1 more source
Further observations on the Therapeutic Value of Radium and Thorium [PDF]
, 1904 J. M. H. MacLeod
openalex +1 more source